

Bradley A Stohr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189318/publications.pdf>

Version: 2024-02-01

38
papers

1,671
citations

430874

18
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

3025
citing authors

#	ARTICLE	IF	CITATIONS
1	Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. <i>Nature</i> , 2014, 512, 198-202.	27.8	519
2	Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. <i>American Journal of Surgical Pathology</i> , 2018, 42, 927-935.	3.7	167
3	Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. <i>Cell Stem Cell</i> , 2020, 26, 27-33.e4.	11.1	155
4	Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 435-445.	3.7	106
5	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. <i>Nature Communications</i> , 2022, 13, 141.	12.8	76
6	Renal Cell Carcinoma With Leiomyomatous Stroma Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. <i>American Journal of Surgical Pathology</i> , 2020, 44, 571-581.	3.7	67
7	Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review. <i>Urology</i> , 2020, 135, 11-19.	1.0	64
8	Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. <i>Modern Pathology</i> , 2016, 29, 1012-1027.	5.5	54
9	The Shelterin TIN2 Subunit Mediates Recruitment of Telomerase to Telomeres. <i>PLoS Genetics</i> , 2015, 11, e1005410.	3.5	47
10	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. <i>European Urology</i> , 2017, 71, 750-759.	1.9	40
11	Nuclear size is sensitive to NTF2 protein levels dependent on Ran binding. <i>Journal of Cell Science</i> , 2016, 129, 1115-27.	2.0	39
12	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 668-675.	1.9	34
13	ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5309-5317.	0.9	32
14	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	5.4	32
15	Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. <i>Modern Pathology</i> , 2017, 30, 407-415.	5.5	28
16	The Terminal Telomeric DNA Sequence Determines the Mechanism of Dysfunctional Telomere Fusion. <i>Molecular Cell</i> , 2010, 39, 307-314.	9.7	27
17	In situ visualization of telomere elongation patterns in human cells. <i>Nucleic Acids Research</i> , 2013, 41, e176-e176.	14.5	27
18	Metabolic imaging with hyperpolarized ¹³ C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience. <i>Cancer</i> , 2021, 127, 2693-2704.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction. <i>Autophagy</i> , 2015, 11, 527-537.	9.1	17
20	Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. <i>Prostate</i> , 2020, 80, 653-659.	2.3	17
21	Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 90-95.	0.4	16
22	Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. <i>Histopathology</i> , 2020, 76, 1084-1090.	2.9	11
23	Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. <i>PLoS ONE</i> , 2018, 13, e0206525.	2.5	9
24	Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. <i>Practical Laboratory Medicine</i> , 2020, 21, e00164.	1.3	9
25	Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. <i>American Journal of Surgical Pathology</i> , 2022, 46, 392-403.	3.7	9
26	FPA144, a humanized monoclonal antibody for both <i>FGFR2</i> -amplified and nonamplified, <i>FGFR2b</i> -overexpressing gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15074-e15074.	1.6	9
27	Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. <i>Investigative and Clinical Urology</i> , 2022, 63, 27.	2.0	8
28	Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. <i>Modern Pathology</i> , 2020, 33, 1802-1810.	5.5	7
29	Reply to Chou et al "Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution" <i>Mod Pathol</i> 2017; in press.. <i>Modern Pathology</i> , 2017, 30, 1509-1511.	5.5	4
30	Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. <i>Pathology</i> , 2021, 53, 214-219.	0.6	4
31	Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. <i>Human Pathology</i> , 2022, 119, 85-93.	2.0	4
32	Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 531-531.	1.6	4
33	Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. <i>Prostate</i> , 2020, 80, 1421-1428.	2.3	1
34	Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17025-e17025.	1.6	1
35	In Situ Visualization of Telomere Length, Telomere Elongation, and TERT Expression in Single Cells. <i>Current Protocols in Cell Biology</i> , 2019, 85, e97.	2.3	0
36	Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11575-11575.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.. Journal of Clinical Oncology, 2019, 37, 88-88.	1.6	0
38	LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathology Research and Practice, 2022, 232, 153831.	2.3	0